Baseline alexithymia and recovery from major depressive disorder: a longitudinal study
Nordic Journal of Psychiatry · 29.10.2026 · 1-9
DOI: 10.1080/08039488.2026.2749588 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nordic Journal of Psychiatry, online erschienen am 29.10.2026. Verfasst von Kirsi Honkalampi und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Educational Sciences and Psychology, University of Eastern Finland, Joensuu, Finland. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Research Council of Finland, Nordic Research Council for Criminology.
Abstract (Originalsprache)
OBJECTIVE: To investigate whether alexithymia is associated with baseline symptom severity or longitudinal treatment outcomes in patients with major depressive disorder (MDD). METHODS: The sample comprised 258 outpatients with MDD (mean age = 31.77, SD = 11.30) followed for six months. Alexithymia was assessed with the Toronto Alexithymia Scale (TAS-20), depressive symptoms with the Beck Depression Inventory (BDI), and psychopathology with the SCL-90-R. RESULTS: The prevalence of alexithymia was 27.9% (n = 72) at baseline, 18.4% (n = 29) at 3 months, and 16.1% (n = 23) at 6 months. Among patients with baseline alexithymia, 40.3% remained alexithymic at 3 months and 31.9% at 6 months. At baseline, alexithymic patients had significantly higher BDI scores and scores on all TAS-20 subscales and SCL-90-R domains. Depressive symptoms decreased significantly during follow-up, with the greatest improvement during the first 3 months. Although alexithymic patients had consistently higher depressive symptom levels, the time × group interaction was not significant, indicating similar improvement in both groups. However, participants with baseline alexithymia were significantly more likely to be lost to follow-up than those without alexithymia. CONCLUSION: Alexithymia was associated with greater baseline psychopathology and persistently higher depressive symptom levels. However, alexithymic and non-alexithymic patients showed similar trajectories of symptom reduction, suggesting that alexithymia does not limit improvement in depressive symptoms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Educational Sciences and Psychology, University of Eastern Finland, Joensuu, Finland.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, Kuopio, Finland.
- Mental health and Wellbeing, Kuopio University Hospital, Kuopio University Hospital, Wellbeing Services County of North Savo, Kuopio, Finland.
- Deakin Institute for Mental and Physical Health and Clinical Translation (Deakin IMPACT), Food & Mood Centre, School of Medicine, Deakin University, Geelong, Australia.
- Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
ORCID-Profile: Kirsi Honkalampi
Förderung
- Research Council of Finland
- Nordic Research Council for Criminology
Zitieren
APA
Honkalampi, K., Savinen, S., Ruusunen, A., Tolmunen, T., Laukkanen, V., Mikola, T., Pakarinen, M., & Lehto, S. M. (2026). Baseline alexithymia and recovery from major depressive disorder: a longitudinal study. Nordic Journal of Psychiatry, 1-9. https://doi.org/10.1080/08039488.2026.2749588
Vancouver
Honkalampi K, Savinen S, Ruusunen A, Tolmunen T, Laukkanen V, Mikola T, et al. Baseline alexithymia and recovery from major depressive disorder: a longitudinal study. Nordic Journal of Psychiatry. 2026:1-9. doi:10.1080/08039488.2026.2749588
BibTeX
@article{Honkalampi2026,
author = {Honkalampi, Kirsi and Savinen, Suvi and Ruusunen, Anu and Tolmunen, Tommi and Laukkanen, Virpi and Mikola, Tuomas and Pakarinen, Maarit and Lehto, Soili M},
title = {Baseline alexithymia and recovery from major depressive disorder: a longitudinal study},
journal = {Nordic Journal of Psychiatry},
year = {2026},
pages = {1--9},
doi = {10.1080/08039488.2026.2749588}
}
EUVIMED